All Search Results
-
PERSEVERE
Randomized Controlled Trial of High-Risk Pulmonary Embolism Comparing FlowTriever System vs. Standard of Care (PERSEVERE)
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
-
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
-
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
-
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
A Phase II study of Naxitamab added to induction Therapy for Subjects with Newly Diagnosed High Risk Neuroblastoma
-
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion (PICASSO) Thrombectomy Trial
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion (PICASSO) Thrombectomy Trial
-
A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions
A novel wearable system for monitoring and alerting for seizures and cardiorespiratory dysfunctions
-
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
-
Project:EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study
Project: EveryChild a Registry, Eligibility Screening, Biology and Outcome Study